Key Takeaways
- Oura launched its first proprietary AI model on February 24, 2026, purpose-built for women's health. It covers the full reproductive spectrum and runs entirely on Oura-controlled infrastructure.
- Wearable algorithms were historically calibrated on male-skewing clinical data (only 34% female representation in sports medicine research), treating hormonal cycle variation as noise rather than signal.
- Cycle-driven biometric changes are measurable: HRV drops ~12% from follicular to luteal phase, resting heart rate rises ~8 bpm, wrist skin temperature shifts ~0.50°C.
- Apple (FDA-cleared wrist-temperature contraception), Whoop (45,000+ cycles analyzed in a Nature study), and others are making parallel investments.
- Reproductive health data carries higher privacy stakes than general wellness data. Most consumer health apps fall outside HIPAA, and 78% of FemTech apps failed GDPR consent audits.
- For developers, cycle-contextualized metrics represent a new data category with fragmented APIs across providers and evolving regulatory requirements.
Is Your HealthTech Product Built for Success in Digital Health?
.avif)
Oura just launched its first proprietary AI model, and they built it entirely around women's health. The model covers menstrual cycles, fertility, pregnancy, and menopause, runs on Oura's own infrastructure, and draws on biometric data that most wearable algorithms have historically misinterpreted. It is a significant product move, but the broader signal matters more: the wearable industry is correcting a data problem that has affected half its users for years. This article breaks down what Oura built, why it took the industry this long, and what it means for developers building health applications.
The Gender Data Gap in Wearable Algorithms
Most wearable health algorithms assume the human body operates on a roughly stable daily rhythm. Heart rate variability, resting heart rate, skin temperature, sleep architecture, all measured against a personal baseline learned over days and weeks.
For roughly half the population, that assumption produces inaccurate results. Women's bodies operate on a ~28-day hormonal cycle that affects every biometric a wearable tracks. HRV drops by approximately 12% from the follicular to the luteal phase (SDNN: 154 ms to 136 ms). Resting heart rate rises by nearly 8 bpm. Wrist skin temperature shifts around 0.50°C post-ovulation. These are changes large enough to trigger "poor recovery" alerts or flag potential illness in most wearable apps, when they are in fact predictable monthly patterns driven by progesterone and estrogen fluctuations.
The root cause is a data foundation problem. In sports and exercise medicine journals between 2014 and 2020, only 34% of study participants were female. Male-only studies outnumbered female-only studies 5 to 1. Wearable companies built their algorithms on this published research, and the algorithms inherited its blind spots. The common justification, that menstrual cycle variability "weakens statistical power," has since been challenged by researchers who found that cycle-driven fluctuations did not substantially increase measurement variability.
What Oura Launched
On February 24, 2026, Oura released its first proprietary AI model, purpose-built for women's health.
The model is integrated into Oura Advisor, the in-app AI assistant, covering menstrual cycles, fertility, pregnancy, and menopause. It was developed using knowledge-graph technology from webAI, built by Oura's clinical and engineering teams, and reviewed by board-certified women's health specialists.
Infrastructure ownership. The AI model runs entirely on Oura-controlled infrastructure. User conversations are not routed through third-party AI providers, and data is not sold, shared, or used to train external models.
Validated cycle tracking as foundation. The model builds on Oura's Cycle Insights feature, which has ovulation detection accuracy above 96% (published in JMIR). The November 2025 update extended predictions to 12-month windows and shortened onboarding from 60 nights to the start of the next menstrual cycle.
Targeted clinical partnerships. Oura has partnered with Midi Health (menopause care), Evernow (hormone replacement therapy), Maven Clinic (family planning), and Progyny (fertility benefits).
A deliberate product pivot. Oura's fastest-growing demographic is now women in their early twenties. The Ring 4 Ceramic is designed and marketed for women. This is a coordinated data, product, and go-to-market strategy shift.
The Broader Industry Movement
Oura is not operating in isolation. Multiple companies are investing in women's health data simultaneously.
Apple has been running the Women's Health Study with Harvard's T.H. Chan School of Public Health. Natural Cycles received FDA 510(k) clearance to use wrist temperature data from Apple Watch Series 8+ for birth control decisions, the first FDA-cleared application of a consumer wearable sensor for contraception.
Whoop published research in npj Digital Medicine (Nature) analyzing over 45,000 menstrual cycles from 11,000+ members. They introduced "cardiovascular amplitude," a metric capturing heart rate and HRV fluctuation across a single cycle, attenuated in older women and those on hormonal birth control.
Garmin, Fitbit/Google, and Samsung all offer cycle tracking of varying depth. The direction across the industry is consistent: cycle data is moving into core health models, not staying as a standalone feature.
Why It Took This Long
The clinical research bias created a data foundation problem: wearable companies built algorithms on studies that underrepresented women, and early product teams optimized for their initial (male-skewing) user base. Cycle tracking was scoped as a discrete feature (a period calendar) rather than a foundational variable that should influence every other health metric.
Fertility prediction also touches sensitive regulatory territory. The FDA classifies software that informs contraceptive decisions differently from general wellness apps. Post-Dobbs, the privacy implications added another layer of caution. And accurate cycle-aware models require longitudinal data across thousands of cycles. Whoop needed 45,000+ cycles to validate their cardiovascular amplitude metric.
Reproductive Health Data and Privacy
Reproductive health data is categorically different from step counts or workout logs.
In the United States, 19 states have implemented post-Dobbs restrictions that create potential legal incentives for accessing reproductive health data. Most period and fertility tracking apps fall outside HIPAA entirely because they are not "covered entities." Under the EU's GDPR, reproductive health data is "special category" data under Article 9. A 2022 audit found that 78% of leading FemTech applications failed to obtain granular consent, and over 60% transmitted unencrypted health information to third-party servers.
Oura hosts their women's health AI entirely on their own infrastructure. Legislation is emerging in multiple US states and at the federal level. But for teams building health features that touch cycle or reproductive data, privacy is an architectural decision (data residency, encryption, access control, jurisdiction) that needs to be designed from the start.
Implications for Health App Development
A new data category is becoming available through wearable APIs: cycle-contextualized health metrics.
This goes beyond period tracking. It is HRV, heart rate, temperature, sleep, and recovery data with cycle phase as a contextual variable. For coaching apps: adjusting training by cycle phase. For AI health assistants: not flagging luteal-phase HRV dips. For clinical research: stratifying outcomes by cycle phase rather than treating hormonal variation as noise.
The API integration challenge follows a familiar pattern. Oura exposes cycle data through dedicated endpoints. Apple uses HealthKit's HKCategoryTypeIdentifier framework. Whoop ties cycle data to their recovery model. Teams needing multi-device cycle data face schema fragmentation with higher privacy stakes. Open-source projects like Open Wearables are working on Oura integration and unified data models, but in early 2026, most teams are still writing custom normalization.
What to Watch
The next phase is cycle-aware algorithms that adjust all health metrics based on reproductive context: readiness scores, sleep analysis, and recovery models calibrated to hormonal fluctuation. Whether open interoperability standards emerge for cycle health data (FHIR profiles, for example) will determine the long-term cost and complexity of building multi-device women's health features. The data models that Oura, Apple, and Whoop settle on over the next 12 months will likely shape the rest of the industry.
